Adagrasib,ADADX,Adagrasib,200mg

Manufacturer: Laos Daxiong Pharmaceutical

Introduction: 200mg*90 tablets

Adagrasib is a highly specific, potent, oral KRAS _G12C inhibitor that is optimized to have persistent target inhibition, a property that may be important for treating cancers with KRAS _G12C mutations because KRAS _G12C protein regenerates every 24-48 hours.

Adagrasib has a long half-life of 24 hours and extensive tissue distribution, and is able to cross the blood-brain barrier, helping to maximize drug efficacy.

Adagrasib is approved by the US FDA for the treatment of previously treated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) carrying the KRAS G12C mutation.